- Raw materials
- Respiratory Tract Agents
- Metizoline
Metizoline API Manufacturers & Suppliers
0 verified results
All Metizoline data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Metizoline | CAS No: 17692-22-7 | GMP-certified suppliers
A medication that provides nasal decongestion through sympathomimetic action, primarily intended for research and development in nasal therapeutic applications.
Therapeutic categories
Product Snapshot
- Metizoline is an oral small molecule formulation
- It is primarily investigated for respiratory therapeutic applications
- The compound is currently in experimental stages and has not received FDA or EMA approval
Clinical Overview
Metizoline remains an experimental drug with limited publicly available clinical data. Its exact clinical indications have not been formally established or documented in the literature. The pharmacodynamics and precise mechanism of action have not been disclosed; however, as a sympathomimetic agent used in nasal formulations, it is generally inferred to act by stimulating alpha-adrenergic receptors in the nasal mucosa, promoting vasoconstriction and thereby reducing nasal congestion.
No detailed absorption, distribution, metabolism, or excretion (ADME) data have been reported for Metizoline. Given its topical nasal application, systemic exposure is expected to be minimal, although quantitative parameters remain undefined. Safety and toxicity profiles have not been clearly described in published sources, and the compound has not received regulatory approval for clinical use. This status indicates that comprehensive preclinical and clinical safety evaluations are pending or incomplete.
No marketed pharmaceutical brands or commercial formulations containing Metizoline are currently documented. Its experimental status suggests it is primarily of interest in research contexts or early-stage development rather than widespread therapeutic use.
For sourcing and procurement of Metizoline as an active pharmaceutical ingredient (API), it is critical to obtain supplies from reliable manufacturers compliant with appropriate regulatory standards. Rigorous quality control measures should be applied to verify chemical purity, identity, and absence of contaminants, given the lack of established pharmacopoeial monographs. Handling and storage conditions must align with stable aromatic heterocyclic compounds to preserve integrity for investigational applications.
Identification & chemistry
| Generic name | Metizoline |
|---|---|
| Molecule type | Small molecule |
| CAS | 17692-22-7 |
| UNII | Z27L8N105U |
| DrugBank ID | DB13614 |
Formulation & handling
- Metizoline is a small molecule with limited aqueous solubility, suggesting formulation strategies to enhance bioavailability may be required.
- Oral administration is likely preferred given its physicochemical properties and lack of peptide or biologic characteristics.
- Stability considerations should focus on protecting the aromatic heterocyclic structure from oxidation or light-induced degradation during storage and handling.
Regulatory status
Metizoline is a type of Respiratory Tract Agents
Respiratory Tract Agents are a vital category of pharmaceutical APIs (Active Pharmaceutical Ingredients) designed to treat respiratory conditions and diseases. These agents are specifically formulated to target the respiratory system, which includes the lungs, airways, and nasal passages. They play a crucial role in managing various respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
Respiratory Tract Agents encompass a wide range of medications, including bronchodilators, corticosteroids, antihistamines, and mucolytics. Bronchodilators are commonly used to relieve airway constriction and facilitate smooth breathing by relaxing the muscles in the airways. Corticosteroids help reduce inflammation in the respiratory system, alleviating symptoms and preventing exacerbations. Antihistamines work by blocking histamine receptors, thus mitigating allergic reactions that often impact the respiratory tract. Mucolytics aid in loosening and thinning mucus, making it easier to expel from the airways.
These APIs are developed through rigorous research and development processes, ensuring their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers rely on advanced technologies and stringent quality control measures to produce high-quality Respiratory Tract Agents. These APIs are subsequently incorporated into various dosage forms, including inhalers, nasal sprays, nebulizers, and oral medications.
Respiratory Tract Agents are essential in the management of respiratory conditions, providing relief from symptoms, improving lung function, and enhancing the overall quality of life for patients. They are prescribed by healthcare professionals and often used in combination therapies to achieve optimal results. As respiratory disorders continue to affect a significant portion of the global population, the development and availability of effective Respiratory Tract Agents play a vital role in addressing these health challenges and improving patient outcomes.
